Evidence map›Paper›PMID 42436982›Full record

ArticleiScience2026

Development of an

Morgan G Thomas, Simon A Levy, Meredith H Jenkins, Morgan Lambert, Bess Frost

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Morgan G ThomasCenter for Alzheimer's Disease Research, Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA.
Simon A LevyDepartment of Cell Systems and Anatomy, University of Texas Health San Antonio, San Antonio, TX, USA.
Meredith H JenkinsCenter for Alzheimer's Disease Research, Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA.
Morgan LambertCenter for Alzheimer's Disease Research, Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA.
Bess FrostCenter for Alzheimer's Disease Research, Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA.

Funding

Resource Component: Acquisition, maintenance and distribution of Drosophila stocksP40OD018537 · OD · TRUSTEES OF INDIANA UNIVERSITY · PI Annette L. Parks · 2014 to 2026
$13.5M
Integrated Graduate Training Program in Neuroscience, UTHSCSAT32NS082145 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI David A Morilak · 2013 to 2026
$1.5M
NIH HHS P40 OD018537NINDS NIH HHS T32 NS082145
6 · The paper itself

Abstract

Huntington's disease is a neurodegenerative disorder caused by a polyglutamine (polyQ) expansion in exon one of the gene that encodes for the protein huntingtin (HTT). PolyQ expansion drives HTT aggregation into multimeric species that range from soluble oligomers to fibrillar, insoluble inclusion bodies. Cellular mechanisms facilitating HTT aggregation are incompletely understood, hindering efforts to develop strategies that prevent inclusion body formation or promote clearance of misfolded protein. To enable future unbiased

Indexed as

DrosophilahuntingtinHuntington’s diseasepolyglutaminesplit-luciferase

Identifiers

PMID42436982
PMCPMC13355796

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.